P-Cure, a global innovator in compact proton therapy solutions, has announced the inauguration of its second production facility in Israel.
JERUSALEM, Israel, June 9, 2025 /PRNewswire-PRWeb/ -- P-Cure, a global innovator in compact proton therapy solutions, has announced the inauguration of its second production facility in Israel. This new building, adjacent to the existing P-Cure facility, is to be dedicated specifically to the manufacturing and assembly of P-Cure's advanced compact proton therapy systems, with a particular focus on in-house production of its proprietary accelerator technology.
This expansion supports P-Cure's strategy to consolidate core production capabilities, enhancing supply chain resilience and reducing dependence on external suppliers, particularly for high-precision components. The new production line is expected to further shorten delivery times, building on P-Cure's current industry-leading production schedules.
The clinical advantages of proton therapy—delivering precise, targeted radiation with significantly reduced dose to healthy tissues and critical organs—make it an optimal treatment option, particularly for pediatric patients, head and neck cancers, and tumors near sensitive organs. However, the high cost of traditional proton therapy systems and the need for large, purpose-built facilities have significantly limited adoption worldwide. P-Cure's compact system, designed to fit into existing linac vaults, directly addresses these economic barriers, making proton therapy more accessible to hospitals and cancer centers globally.
Additionally, the new facility will support ongoing research and development initiatives, including the development of helium particle acceleration technologies. In-house production will further reduce system costs and accelerate innovation cycles, contributing to the company's mission to make proton therapy more economically viable and clinically accessible.
"This facility significantly strengthens P-Cure's manufacturing independence and our ability to deliver systems faster while maintaining the highest quality standards," said Udi Oren, P-Cure's Chief Operating Officer. "Concentrating critical production processes under one roof makes us more agile and better equipped to handle global supply chain challenges."
Dr. Dmitry Schwartz, P-Cure's Chief Accelerator Scientist, emphasized the importance of in-house accelerator production: "The accelerator is the heart of the proton therapy system. By keeping its production and ongoing development within P-Cure, we can accelerate innovation, maintain tighter quality control, and continually reduce costs—helping to make proton therapy available to more patients worldwide."
About P-Cure
P-Cure is a global leader in compact proton therapy technology, providing a linac vault-compatible solution that brings the benefits of proton therapy into existing radiation oncology departments. With a focus on clinical accessibility, patient comfort, and cost-efficiency, P-Cure systems are designed to deliver targeted radiation treatments supporting better clinical outcomes with reduced toxicity. For more information, visit: www.p-cure.com
Media Contact
Stephen Jacobs, P-Cure, 1 9173468619, [email protected], p-cure.com
SOURCE P-Cure
Share this article